OBJECTIVE: Lysyl oxidase (LOX) is an extracellular enzyme critical for the crosslinking of collagens and elastin. A singlenucleotide polymorphism of LOX G473A is associated with various diseases. This retrospective study investigated the association between LOX G473A polymorphism and susceptibility to ovarian cancer in the Han Chinese population. METHODS: The LOX variant G473A was detected by polymerase chain reactionrestriction fragment length polymorphism in patients with ovarian cancer and healthy control subjects. RESULTS: The frequencies of the LOX 473AA genotype and the A allele were significantly higher in patients with ovarian cancer (n = 318) than in control subjects (n = 406) (odds ratio [OR] 2.30, 95% confidence interval [CI] 1.36, 3.87; OR 1.57, 95% CI 1.23, 2.00; respectively). The prevalence of the GA genotype, AA genotype and A allele were significantly higher in patients with more advanced stages of ovarian cancer compared with those with primary stage disease. CONCLUSIONS: This study suggests that LOX G473A polymorphism is a new risk factor for ovarian cancer and that LOX protein might be a possible therapeutic target in ovarian cancer.
Introduction
Ovarian cancer continues to be the leading cause of death among the gynaecological cancers, despite improvements in surgery and chemotherapy. 1, 2 Over 75% of ovarian cancer patients are classified as being International Federation of Gynecology and Obstetrics (FIGO) stage III and IV at the time of diagnosis, and 2.3 the 5-year survival rate remains approximately 30% for patients with distant metastatic disease. 4 Although the exact causes of ovarian cancer have not been identified, it is possible that genetic alterations may be involved in the aetiology of this disease. 5, 6 Lysyl oxidase (LOX) is synthesized as a 48 kDa preproprotein and secreted as an inactive 50 kDa proenzyme protein (proLOX). 7 ProLOX is processed mainly by procollagen C-proteinase or other extracellular proteases (e.g. mammalian Tolloid protein [mTLD]1 and mTLD2) into a catalytically active 32 kDa protein (LOX) and an 18 kDa LOX propeptide domain (LOX-PP). 7 LOX is a copper-dependent amine oxidase that catalyses the oxidative X Wang, J-L Cong, L-Y Qu et al. LOX G473A polymorphism and ovarian cancer susceptibility deamination of the extracellular matrix molecules collagen and elastin to form reactive aldehydes. 7 The aldehyde residues form inter-and intracross linkages to generate insoluble fibres that are essential for maturation of the extracellular matrix. 7 -10 In addition, LOX is a multifunctional enzyme involved in diverse biological functions such as gene regulation, signal transduction and cell senescence. 7 In the ovary, LOX protein is known to regulate collagen degradation during the ovulatory process. 7 One study has shown that the level of LOX mRNA is increased in the ovaries of rats with polycystic ovary syndrome. 9 It has been reported that LOX has two opposing functions in cancer as it can act as both a tumour suppressor and a promoter of metastasis. 8, 11, 12 Thus, any changes in LOX gene expression and/or LOX protein function may potentially affect the development of cancer.
The LOX gene is located on chromosome 5q23. 10 A single-nucleotide polymorphism (SNP) of the LOX gene, the G473A polymorphism, causes an arginine (Arg)158 glutamine (Gln) substitution in a highly conserved region within LOX-PP. 13 Studies have shown that this SNP is associated with an increased risk of breast cancer in African-American and Han Chinese females. 13, 14 The relationship between the LOX G473A polymorphism and the occurrence of ovarian cancer remains unknown, as there have been no reports on the prevalence of the LOX G473A SNP in ovarian cancer. Clarification of the relationship between the LOX G473A SNP and ovarian cancer may suggest a role for LOX in the aetiology of ovarian cancer, and may provide clues to guide the treatment of this disease. Consequently, the present study analysed the distribution of the LOX G473A polymorphism in Han Chinese patients with ovarian cancer and in healthy control subjects.
Patients and methods

STUDY POPULATION
This retrospective case-control study included consecutive patients with ovarian cancer and healthy control subjects recruited from the Yantai Yuhuangding Hospital (Qingdao University, Shandong Province, China) between January 2007 and May 2011. The diagnosis of epithelial ovarian cancer was confirmed by histopathological examination in the Department of Gynaecology, Yantai Yuhuangding Hospital. Tumour histological status, grade and stage based on the FIGO staging system 15 were determined. The control population was recruited from women who underwent general health examinations at the same hospital and were confirmed by questionnaire to have no malignant disease. All study participants were of Han Chinese ethnicity and were unrelated. Subjects who were relatives of patients were excluded.
Written informed consent (which covered the posthumous use of samples) was obtained from each participant. The study was approved by the Review Board of Yantai Yuhuangding Hospital (2007-YLH-06).
GENOTYPING ANALYSIS
Blood samples, collected by standard venipuncture using Puyang blood collection tubes (Puyang Medical Technology, Guangzhou, China) containing 3.2% sodium citrate, were retrieved from hospital archives. Genomic DNA was extracted from 5 ml of frozen whole blood using a DNA extraction kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The LOX G473A polymorphism (reference SNP number: rs1800449) was detected using a polymerase chain reaction (PCR)-LOX G473A polymorphism and ovarian cancer susceptibility restriction fragment length poly morphism method. The two PCR primers were designed based on the GenBank ® reference sequence for LOX using Primer Premier software, version 5.0 (Premier Biosoft International, Palo Alto, CA, USA). The primers were as follows:
forward primer 5′-CTCACAGTACCAGCCTCAGCG-3′; reverse primer 5′-CCAGGTCTGGGCCTTTCATA-3′. The PCR was performed in a total reaction volume of 35 µl containing 100 ng genomic DNA, 12.5 pmol of each primer, 0.1 mM of each deoxyribonucleotide triphosphate, 1 × PCR buffer, 1.0 mmol/l magnesium chloride, and 1.5 U of Taq DNA polymerase (Fermentas International, Burlington, Ontario, Canada). Reactions were conducted using a Biometra T3000 thermal cycler (Biometra, Göttingen, Germany) under the following conditions: an initial denaturation step at 95°C for 10 min, followed by 30 cycles of denaturation at 95°C for 30 s, annealing at 57°C for 30 s, and elongation at 72°C for 30 s, followed by a final elongation step at 72°C for 10 min. The efficiency of the PCR was confirmed by gel electrophoresis on a 1.5% agarose gel. After DNA amplification, the PCR products were digested overnight at 37°C with 10 U of the specific restriction endonuclease PstI (Fermentas International), which cuts the A allele. The digestion products were then separated on a 2% agarose gel stained with ethidium bromide and visualized under ultraviolet light. Genotypes that were homozygous for the A allele were represented by DNA bands with sizes at 291 and 114 base pairs (bp), an uncut fragment of 405 bp indicated the homozygous G alleles, while heterozygous genotypes were identified by a combination of 405, 291 and 114 bp fragments. To confirm the genotyping results, 20% of PCR-amplified DNA samples were randomly selected by computer and sent for DNA sequencing to the Qingdao Zhongding Company (Qingdao, China). Results between PCR and DNA sequencing analysis were 100% concordant.
STRATIFICATION ANALYSIS
The association between the LOX G473A polymorphism and different clinicopathological features in patients with ovarian cancer was also investigated in a stratification analysis, utilizing tumour histological status, grade and stage. 15
STATISTICAL ANALYSES
All statistical analyses were carried out using the SPSS ® software package, version 19.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Comparisons of the demographic data between the two study groups were undertaken using the χ 2 -test and the Student's t-test. The polymorphism was tested for deviation from the Hardy-Weinberg equilibrium by comparing the observed and expected genotype frequencies using the χ 2 -test. For SNP analysis, the frequencies of the genotypes and alleles of the LOX G473A polymorphism were compared between the two groups using the χ 2 -test, and the odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional logistic regression analysis. A P-value < 0.05 was considered to be statistically significant.
Results
A total of 318 patients with ovarian cancer and 406 control subjects were included in the study. All participants were Han Chinese. Demographic and selected clinical characteristics are presented in Table 1 . There were no significant between-group differences in age, body mass index or haematological parameters. LOX G473A polymorphism and ovarian cancer susceptibility
The distribution of the LOX G473A variant genotypes among patients with ovarian cancer and control subjects was in Hardy-Weinberg equilibrium. The frequencies of the three genotypes and the two alleles for the two groups are presented in Table 2 . The frequencies of the LOX 473AA genotype and the A allele were significantly higher in patients with ovarian cancer than in control subjects (OR 2.30, 95% CI 1.36, 3.87; OR 1.57, 95% CI 1.23, 2.00, respectively; Table 2 ).
Findings of the stratification analysis are presented in Table 3 . There was no significant difference in the frequency of the LOX G473A polymorphism in patients with ovarian cancer based on different tumour histology or tumour grade. Patients with advanced disease (FIGO stages III + IV) had significantly increased frequencies of the GA genotype, AA genotype and A allele compared with patients with FIGO stages I + II disease.
Discussion
The present case-control study demonstrated that the LOX 473 AA genotype and the A allele were associated with increased susceptibility to ovarian cancer in the Han Chinese population. To our knowledge, the present study is the first report demonstrating that polymorphisms in the LOX gene can be risk factors for ovarian cancer. The present study also showed a 
TABLE 1: Demographic and clinical characteristics of the Han Chinese patients with ovarian cancer and healthy control subjects who participated in the present study investigating lysyl oxidase (LOX) gene G473A polymorphism and ovarian cancer susceptibility LOX G473A polymorphism and ovarian cancer susceptibility
correlation between the LOX G473A polymorphism and more advanced stages of ovarian cancer, suggesting that the LOX protein may play a critical role in regulating the metastasis and prognosis of this disease. Lysyl oxidase is critical for the proper functioning of the extracellular matrix, which plays various physiological roles in humans and may be directly or indirectly involved in different cancers. 8 -10 Decreased levels of LOX protein have been associated with different types of cancer (e.g. head and , perhaps due to the loss of inhibition of a signalling pathway that induces neoplastic formation. 8, 16 LOX can also promote the progression and invasiveness of some cancers (e.g. oral and oropharyngeal cancer), in which LOX is upregulated, compared with less aggressive cancers or normal tissue. 16 In the ovary, LOX protein is known to regulate collagen degradation during the ovulatory process: 9 increased levels of LOX mRNA have been observed in the ovaries of rats with polycystic ovary syndrome. 9 The excess synthesis of collagen in polycystic ovarian tissue is partly due to the interaction of angiotensin-converting enzyme signalling and LOX, which stimulates LOX activity. 8 -10 In addition, LOX plays a crucial role in follicular development because extracellular matrix needs to be present around the follicular basement membrane to regulate paracrine signals. 11 Disruption of the normal activities of LOX in the ovaries can lead to abnormalities that may eventually develop into cancer. The present study showed that LOX G473A polymorphism is associated with increased susceptibility to ovarian cancer. Furthermore, cancer progression is closely related to its microenvironment, such as extracellular matrix around the tumour. 17 The hypoxic environment of the tumour increases LOX signalling, which stimulates extracellular matrix remodelling and the activation of focal adhesion kinase. 18 The altered extracellular matrix enhances tumour invasion. It is possible that the LOX G473A polymorphism might reinforce LOX signalling which may, in turn, affect the metastasis of ovarian cancer.
The exact molecular mechanism of how the LOX G473A polymorphism contributes to increased susceptibility to ovarian cancer remains unknown. The propeptide domain LOX-PP has been shown to inhibit the transforming activity of the Ras oncogene in breast, pancreatic, lung and prostate cancer cells 19 -22 and to increase the susceptibility of some of these cancer cells to certain chemotherapy agents, such as doxorubicin. 20 Min et al. 13 suggested that the Arg158Gln substitution impairs the tumour suppression ability of LOX-PP in breast cancer. It is possible that the contribution of the LOX G473A polymorphism to ovarian cancer has a similar molecular mechanism.
In conclusion, the present case-control study has demonstrated that the LOX 473 AA genotype and the A allele are associated with an increased risk of ovarian cancer in the Han Chinese population. The LOX G473A polymorphism was also shown to correlate with metastasis in ovarian cancer. These results provide important insights into understanding of the genetics of ovarian cancer and might be useful for the development of LOX as a possible therapeutic target in this disease.
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